GM-CSF/IL-4/LPS–matured DCs provide superior protection against AML compared with DCs generated using Flt3L and matured with LPS.
DCs were generated using GM-CSF/IL-4 or Flt3L and matured with LPS. DCs were then pulsed with AML (C1498) cell lysate for 18 hours then administered intravenously (0.5 × 106 cells/mouse) 14 and 7 days prior to tumor challenge with 1 × 106 C1498 cells/mouse. Mice receiving either DC vaccination had significantly improved survival compared with nonvaccinated controls (P < .0001). Mice receiving GM-CSF/IL-4/LPS–generated DCs had significantly improved survival compared with mice that were vaccinated with DCs generated using Flt3L and LPS (P = .002). Data are pooled results of 2 independent experiments (20 total mice/group).
